Mylan settles with Eisai in Targretin case

Mylan Pharmaceuticals and its partner Banner Pharmacaps Inc, a subsidiary of Patheon Inc, have entered into a settlement and licence agreement with Japanese pharmaceutical company Eisai Inc and Valeant Pharmaceuticals Luxembourg S.a.r.l.

The agreement ends patent litigation related to Bexarotene, the generic version of Targretin, a medicine used in the treatment of skin problems that arise from cutaneous T-cell lymphoma.

Under the agreement Mylan and Banner may start selling a generic version of Targretin on July 9, 2015, “or earlier under certain circumstances”, Mylan said in a statement.

The agreement is subject to review by the US Department of Justice and the Federal Trade Commission.

According to IMS Health, Targretin had US sales of approximately $53.6 million for the 12 months ending September 30, 2013.

Mylan did not respond to LSIPR’s request for comment.